Eli Lilly said its next generation weight-loss drug retatrutide resulted in significant weight loss and reduced knee pain in ...

Eli Lilly is investing $6B in a Huntsville, Ala., plant to make weight-loss and other medicines. Here’s what we know about ...

The site is the third of four new facilities in the U.S. that the pharmaceutical company plans to announce, Eli Lilly said.

French biotech company Abivax's shares rose by over 20% on Wednesday on market rumours that U.S. pharma giant Eli Lilly could ...

Discover why Eli Lilly's stock downturn may present new opportunities. Learn about valuation, Zepbound pricing, and 2026 ...

What Happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3% in the afternoon session after the ...

Bank of America sees Eli Lilly's obesity drug growth underestimated, forecasting $3 billion Orfoglipron revenue by 2026 as new therapies expand global market leadership.

Eli Lilly said on Tuesday it will invest more than $6 billion in a new active drug ingredient manufacturing facility in ...

Eli Lilly 's (NYSE: LLY) share price has soared over the past five years (up 530%). In fact, it's hard to find a single ...

Eli Lilly's innovation and pipeline diversification support long-term growth, despite patent risks and competition. Read more ...

Step aside, semaglutide—retatrutide is showing the most impressive weight loss results of any obesity drug to date.

The maker of Zepbound reported results from a study of retatrutide, which targets three hormones in the body and led to much more weight loss than any approved drug.